

NIH Common Fund Epigenomics Program

**John Satterlee Ph.D.
Epigenomics Program Co-coordinator
National Institute on Drug Abuse/NIH**

**NIH Council of Councils
May 14, 2013**

NIH Epigenomics Working Group


Co-Chairs: Nora Volkow (NIDA), Linda Birnbaum (NIEHS), James Battey (NIDCD)

Co-Coordination: John Satterlee (NIDA), Pat Mastin (NIEHS)

Christine Colvis	NCATS	Roderic Pettigrew	NIBIB	Astrid Haugen	NIEHS
Carol Pontzer	NCCAM	Carol Kasten-Sportes	NICHD	Jerry Heindel	NIEHS
Grace Ault	NCI	Lisa Freund	NICHD	Laurie Johnson	NIEHS
Jennifer Couch	NCI	Susan Taymans	NICHD	Kimberly McAllister	NIEHS
Paul Okano	NCI	Mark Caulder	NIDA	Srikanth Nadadur	NIEHS
Richard Piekarz	NCI	Genevieve deAlmeida-Morris	NIDA	Kristi Pettibone	NIEHS
Sharon Ross	NCI	Donna Jones	NIDA	Fred Tyson	NIEHS
Mukesh Verma	NCI	Jonathan Pollock	NIDA	Leroy Worth	NIEHS
Hemin Chin	NEI	Dena Procaccini	NIDA	Anthony Carter	NIGMS
Elise Feingold	NHGRI	Joni Rutter	NIDA	Andrea Beckel-Mitchener	NIMH
Mike Pazin	NHGRI	David Shurtleff	NIDA	Michelle Freund	NIMH
Weiniu Gan	NHLBI	Bracie Watson	NIDCD	Thomas Lehner	NIMH
Susan Old	NHLBI	Lillian Shum	NIDCR	Roger Little	NIMH
Pothur Srinivas	NHLBI	Kristin Abraham	NIDDK	Aleksandra Vicentic	NIMH
Anna McCormick	NIA	Olivier Blondel	NIDDK	Robert Riddle	NINDS
Suzana Petanceska	NIA	Jessica Faupel-Badger	NIDDK	Randall Stewart	NINDS
Conrad Malia	NIAID	Philip Smith	NIDDK	Stephanie Courchesne	OSC
Nasrin Nabavi	NIAID	Julie Wallace	NIDDK	Patricia Labosky	OSC
Ashley Xia	NIAID	Lisa Chadwick	NIEHS	Johanna Dwyer	ODS
William Sharrock	NIAMS	Gwen Collman	NIEHS	Deborah Olster	OBSSR
Guoying Liu	NIBIB	Christie Drew	NIEHS		

NIH Common Fund Epigenomics Program


**68 grants
\$200M**



Discovery of Novel Epigenetic Marks

GOAL: Discover potential novel epigenetic marks

- 67 new histone modifications
Lysine crotonylation
(Cell, Zhao)
- Lysine propionylation
- Lysine butyrylation
- PolyADP ribosylation
- Histone 3 Arginine 2 dimethylation




Epigenomics of Human Health and Disease

GOAL: Transform our understanding of the epigenomic basis of disease

➤ 2009 CF/IC split
➤ 2011 IC only

Total: 33 R01s, 12 ICs

Alzheimer's
Cardiovascular
Environmental toxins
Asthma
Cancer
Substance abuse
Psychiatric
Autism
Insulin resistance
Autoimmune
Glaucoma




Altered epigenetic states associated with:

- Gestational age at birth (*Feinberg/Fallin*)
- Hepatocellular carcinoma (*Meltzer*)
- Breast cancer (*Huang*)
- Schizophrenia and bipolar disorder (*Mill*)
- Alzheimer's disease (*De Jager/Bennett*)

Technology Development in Epigenetics

GOAL: Develop revolutionary technologies with the potential to significantly change epigenetics research.


- 2008 General epigenetic technologies
- 2011 Epigenetic imaging
- 2013 Epigenetic manipulation (new)



Gelovani lab


- Histone dynamics (*Science, Henikoff*)
- Single molecule epigenomics (*PNAS, Soloway*)
- SXRT of epigenomic organization (*Cell, Larabell/Lomvardas*)
- PET imaging of histone deacetylases (*Neuroimage, Gelovani*)

NIH Common Fund Epigenomics Program



Reference Epigenome Mapping Centers

GOAL: Generate comprehensive epigenomic maps for “normal” human cells and tissues



- First human methylomes (*Nature* 2009)
- 42 methylomes completed
- 79 comprehensive epigenome datasets
- Data publically accessible: <http://www.roadmapepigenomics.org/>

Program Integration and Outreach

Yearly “Investigators” Meetings:

Next: Oct 20-21, 2013 Boston, MA

Workshops:

ENCODE/Epigenomics Programs co-sponsored tutorial on using these datasets (ASHG)

International Efforts:

Members:

**CF Epigenomics,
European Union,
Canada, Germany,
Japan, Italy, South Korea**

Future: Transition and Translation

Transition from Common Fund to NIH ICs


NICHD 2009	Epigenetic Processes in Development (R21)
NINR 2010	Epigenetic Factors Associated with Complications of Chronic Disorders (R01)
NIDA 2010	Exploring Epigenomic Processes and Non-Coding RNAs in HIV/AIDS (R01 and R21)
NIMH 2011	Epigenomic Modifications in Neurodevelopment (R01)
NIEHS 2012	Chromatin Structure, Genomics, and Transcriptional Responses to the Environment (R01)
NIDA 2012	Drugs of Abuse and Transgenerational Phenotypes (R01)
NIEHS 2012	Transgenerational Inheritance in Mammals After Environmental Exposure (R01)
NIAAA 2012	Transgenerational Effects of Alcohol (R01 and R21)
NIDCR 2013	Epigenomics of Virus-Associated Oral Diseases (R01)

The Potential for Translational Epigenomics

Workshop 2011: ‘From Epigenomic Discovery to Improvements in Human Health’

Diagnostics, Therapeutics, Prevention for IC-specific Diseases

Epigenomics Program Publications to Date



Nature 10
Cell 13
Science 2
Nat. Biotech. 6

Using Epigenomics Data to Interpret GWAS Hits

Systematic Localization of Common Disease-Associated Variation in Regulatory DNA

Matthew T. Maurano,^{1*} Richard Humbert,^{1*} Eric Rynes,^{1*} Robert E. Thurman,¹ Eric Haugen,¹ Hao Wang,¹ Alex P. Reynolds,¹ Richard Sandstrom,¹ Hongzhu Qu,^{1,2} Jennifer Brody,³ Anthony Shafer,¹ Fidencio Neri,¹ Kristen Lee,¹ Tanya Kutayavin,¹ Sandra Stehling-Sun,¹ Audra K. Johnson,¹ Theresa K. Canfield,¹ Erika Giste,¹ Morgan Diegel,¹ Daniel Bates,¹ R. Scott Hansen,⁴ Shane Neph,¹ Peter J. Sabo,¹ Shelly Heimfeld,⁵ Antony Raubitschek,⁶ Steven Ziegler,⁶ Chris Cotsapas,^{7,8} Nona S. Delahia,^{3,9} Ian Glass,¹⁰ Shamil R. Sunyaev,¹¹ Rajinder Kaur,⁴ John A. Stamatoyannopoulos^{1,12†}

Genome-wide association studies have identified many noncoding variants associated with common diseases and traits. We show that these variants are concentrated in regulatory DNA marked by deoxyribonuclease I (DNase I) hypersensitive sites (DHSs). Eighty-eight percent of such DHSs are active during fetal development and are enriched in variants associated with gestational exposure-related phenotypes. We identified distant gene targets for hundreds of variant-containing DHSs that may explain phenotype associations. Disease-associated variants systematically perturb transcription factor recognition sequences, frequently alter allelic chromatin states, and form regulatory networks. We also demonstrated tissue-selective enrichment of more weakly disease-associated variants within DHSs and the de novo identification of pathogenic cell types for Crohn's disease, multiple sclerosis, and an electrocardiogram trait, without prior knowledge of physiological mechanisms. Our results suggest pervasive involvement of regulatory DNA variation in common human disease and provide pathogenic insights into diverse disorders.

nome. In total, we identified 3,899,693 distinct DHS positions along the genome (collectively spanning 42.2%), each of which was detected in one or more cell or tissue types (median = 5).

Disease- and trait-associated variants are concentrated in regulatory DNA. We examined the distribution of 5654 noncoding genome-wide significant associations [5134 unique single-nucleotide polymorphisms (SNPs); fig. S1 and table S2] for 207 diseases and 447 quantitative traits (2) with the deep genome-scale maps of regulatory DNA marked by DHSs. This revealed a collective 40% enrichment of GWAS SNPs in DHSs (fig. S1C, $P < 10^{-55}$, binomial, compared to the distribution of HapMap SNPs). Fully 76.6% of all noncoding GWAS SNPs either lie within a DHS (57.1%, 2931 SNPs) or are in complete linkage disequilibrium (LD) with SNPs in a nearby DHS (19.5%, 999 SNPs) (Fig. 1A) (12). To confirm this enrichment, we sampled variants from the 1000 Genomes Project (13) with the same genomic feature localization (intronic versus intergenic), distance from the nearest transcriptional start site, and allele frequency in individuals of European ancestry. We confirmed significant enrichment both for SNPs within DHSs ($P < 10^{-59}$, simulation) and also including variants in complete LD ($r^2 = 1$) with SNPs in DHSs ($P < 10^{-37}$, simulation) (fig. S2).

In total, 47.5% of GWAS SNPs fall within